Asian Organization for Crohn's and Colitis and Asia Pacific Association of Gastroenterology consensus on tuberculosis infection in patients with inflammatory bowel disease receiving anti-tumor necrosis factor treatment. Part 2: management
Open Access
- 1 January 2018
- journal article
- review article
- Published by Korean Association for the Study of Intestinal Diseases in Intestinal Research
- Vol. 16 (1), 17-25
- https://doi.org/10.5217/ir.2018.16.1.17
Abstract
Because anti-tumor necrosis factor (anti-TNF) therapy has become increasingly popular in many Asian countries, the risk of developing active tuberculosis (TB) among anti-TNF users may raise serious health problems in this region. Thus, the Asian Organization for Crohn's and Colitis and the Asia Pacific Association of Gastroenterology have developed a set of consensus statements about risk assessment, detection and prevention of latent TB infection, and management of active TB infection in patients with inflammatory bowel disease (IBD) receiving anti-TNF treatment. Twenty-three consensus statements were initially drafted and then discussed by the committee members. The quality of evidence and the strength of recommendations were assessed by using the Grading of Recommendations Assessment, Development, and Evaluation methodology. Web-based consensus voting was performed by 211 IBD specialists from 9 Asian countries concerning each statement. A consensus statement was accepted if at least 75% of the participants agreed. Part 2 of the statements comprised 3 parts: management of latent TB in preparation for anti-TNF therapy, monitoring during anti-TNF therapy, and management of an active TB infection after anti-TNF therapy. These consensus statements will help clinicians optimize patient outcomes by reducing the morbidity and mortality related to TB infections in patients with IBD receiving anti-TNF treatment.Keywords
Funding Information
- Ministry of Health and Welfare (A120176)
This publication has 64 references indexed in Scilit:
- 2012 Update of the 2008 American College of Rheumatology recommendations for the use of disease‐modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritisArthritis Care & Research, 2012
- Three Months of Rifapentine and Isoniazid for Latent Tuberculosis InfectionThe New England Journal of Medicine, 2011
- Biphasic emergence of active tuberculosis in rheumatoid arthritis patients receiving TNFα inhibitors: the utility of IFNγ assayAnnals Of The Rheumatic Diseases, 2011
- Serial Interferon-gamma Release Assays for the Diagnosis of Latent Tuberculosis Infection in Patients Treated with Immunosuppressive AgentsAnnals of Laboratory Medicine, 2011
- Saudi guidelines for testing and treatment of latent tuberculosis infectionAnnals of Saudi Medicine, 2010
- Tumor Necrosis Factor Blockade in Chronic Murine Tuberculosis Enhances Granulomatous Inflammation and Disorganizes Granulomas in the LungsInfection and Immunity, 2008
- Reduction of Chemokine Secretion in Response to Mycobacteria in Infliximab-Treated PatientsClinical and Vaccine Immunology, 2008
- Immune Reconstitution Inflammatory Syndrome in HIV-Infected Patients Receiving Antiretroviral TherapyDrugs, 2008
- Why Is Long-Term Therapy Required to Cure Tuberculosis?PLoS Medicine, 2007
- InfliximabDrugs, 2000